EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study First CNS Lymphoma Patient Dosed in Phas...
Stay updated with breaking news from Hakim Bouterfa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study First CNS Lymphoma Patient Dosed in Phas...
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyFirst CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher) 22.11.2023 / 16:02 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin/Würzburg, 22 November 202...
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: Study First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium Anditixafortide ...
The company founder and Chairman of the Supervisory Board of the radiation and medical technology specialist Eckert & Ziegler is moving from the parent company to the spin-off subsidiary for clinical...
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: AGM/EGM/Personnel ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share.... | June 7, 2023